BioXcel Therapeutics Inc
bioxceltherapeutics.comBioXcel Therapeutics (NASDAQ: BTAI) is a clinical-stage biopharmaceutical company that develops central nervous system and immuno-oncology drug candidates using an AI-assisted discovery platform. Its only approved and commercialized product is IGALMI (dexmedetomidine sublingual film), FDA-approved for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder, with commercial sales launched in July 2022. Revenue is generated through net product sales of IGALMI, which totaled $642 thousand in FY2025 and $2,266 thousand in FY2024, a decline attributed to reduced bulk sales, higher GPO discounts, and reduced commercial activities following Clinical Reprioritizations in May and September 2024. The company operates at a net loss, funding operations through equity issuances. CEO Vimal Mehta, Ph.D., also leads affiliated entity BioXcel LLC, which owns the EvolverAI drug discovery engine used to identify BTAI's pipeline candidates including BXCL501, BXCL502, BXCL701, and BXCL702.
Products & Services
IGALMI (dexmedetomidine sublingual film), FDA-approved and commercially launched July 2022, for acute agitation in schizophrenia or bipolar I/II. Pipeline candidates include BXCL501 (agitation associated with Alzheimer's disease, among other indications), BXCL502, BXCL701 (emergent neuroendocrine prostate cancer), and BXCL702. Drug discovery relies on EvolverAI, a proprietary AI platform owned by affiliated entity BioXcel LLC.
Revenue Model
Transactional product revenue from net sales of IGALMI to hospitals and Integrated Delivery Networks via a Corporate Account Director team. IGALMI net product revenue was $642 thousand in FY2025 and $2,266 thousand in FY2024 per the 10-K filed 2026-03-27.
Customers & Markets
Hospitals and Integrated Delivery Networks (IDNs) in the institutional psychiatric and acute care market. End patients present with agitation associated with schizophrenia, bipolar disorder, or dementia. Commercial strategy shifted to a top-down hospital/contracting model following the 2024 Clinical Reprioritization.
Financial Snapshot
Loading...
